New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials

NCT ID NCT07524348

Recruiting now Disease control Sponsor: Samsung Bioepis Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the drug can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Research Site
RECRUITING

Scottsdale, Arizona, 85258, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
RECRUITING

Adelaide, Australia
Research Site
RECRUITING

Melbourne, Australia
Research Site
RECRUITING

Barcelona, Spain
Research Site
RECRUITING

Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.